Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Melatonin controlled-release - Neurim Pharmaceuticals

Next Previous
Drug Profile

Melatonin controlled-release - Neurim Pharmaceuticals

Alternative Names: Circadin; KI 1001 - Kuhnil; KI1001; Melatonin extended-release; Melatonin prolonged-release; Melatonin sustained-release; Orlogin; Paediatric Prolonged-Release Melatonin; PedPRM; Rx PedPRM; Slenyto

Latest Information Update: 22 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neurim Pharmaceuticals
  • Developer Kuhnil Pharmaceutical Company; Neurim Pharmaceuticals; Sigma Pharmaceuticals
  • Class Anti-inflammatories; Chemoprotectants; Hormones; Radioprotectives; Sleep disorder therapies; Tryptamines
  • Mechanism of Action Antioxidants; Melatonin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sleep disorders
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Insomnia
  • Phase III Sleep disorders
  • Discontinued Tardive dyskinesia

Most Recent Events

  • 13 Jan 2026 Melatonin controlled-release (SLENYTO) licensed to Kye Pharmaceuticals in Canada
  • 10 Sep 2025 Registered for Insomnia (In children, In adolescents) in Canada (PO)
  • 10 Sep 2025 Neurim Pharmaceuticals plans to launch Melatonin controlled release in Canada for Insomnia

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top